AKT competitive inhibitors are majorly listed below: Capivasertib (AZD5363) 71, a selective PAN-AKT inhibitor that entered clinical trials for the treatment of breast, gastric, and prostate cancers; Afuresertib (GSK2110183) 72, a monotherapy of relapsed or refractory multiple myeloma treatment; Uprosertib (GSK2141795), which remains in phase I and II studies 73; and the AKT inhibitor Ipatasertib (GDC-0068, RG7440), a monotherapy for the treatment of triple-negative breast cancer, still being in phase I and II studies 74. Here, AKT1 is linked to prostate carcinoma.